(Q36390875)

13 August 2017

1 reference

title

Parkinson's disease management strategies (English)

1 reference

13 August 2017

1 reference

Alex Rajput

1

1 reference

13 August 2017

Ali H Rajput

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

91-99

1 reference

Toward a definition of Parkinson's disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Rationale for current therapies in Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Clinical-pathological study of levodopa complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Is levodopa toxic to human substantia nigra?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Lesion therapy for Parkinson's disease and other movement disorders: update and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Temporal variability of gait in Parkinson disease: effects of a rehabilitation programme based on rhythmic sound cues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

Wheeled and standard walkers in Parkinson's disease patients with gait freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.91

21 January 2018

Identifiers

DOI

10.1586/14737175.6.1.91

1 reference

13 August 2017

1 reference